Wolfe Research analyst Mike Polark upgraded Insulet (PODD) to Outperform from Peer Perform with a $350 price target Insulet is the “share-taking asset” in the pump space and still has “tons” of revenue and margin opportunity ahead, including a potential inflection from type 2 diabetes, the analyst tells investors in a research note. The firm says it “under-reacted” to the company’s positive Q1 preannouncement that accompanied the CEO transition news.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PODD:
- Insulet’s Strong Performance and Growth Potential Justifies Buy Rating
- Analysts Turn Bullish on Insulet Stock (PODD) after Strong Q1 Earnings
- Insulet’s Earnings Call Reveals Strong Growth and Expansion
- Early notable gainers among liquid option names on May 9th
- Insulet price target raised to $330 from $325 at RBC Capital